UCB appoints Peter Theil as head of non-clinical development
pharmafile | November 28, 2011 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | UCB
Peter Theil has joined UCB as its new vice president and head of non-clinical development for the firm’s new medicines research division.
He joins the company from Roche’s biologics arm Genentech, where he was head of early development, pharmacokinetic/pharmacodynamics sciences.
At UCB he will be part of the new medicine’s leadership team and will be based in Belgium.
UCB said Theil’s scientific knowledge, organisational and leadership skills would invaluable in continuing it unique emphasis and success in developing both small and large molecules.
Related Content

UCB presents positive results for fenfluramine in CDKL5 deficiency disorder
UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can …

UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …

Rare and severe epilepsies – current treatments and advance therapeutics
The current forms of immunotherapy, how T cell therapy works and what the future holds






